We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > lymphoma trial

News List

Regeneron records 80% complete response rate in lymphoma trial fiercebiotech
January 03, 2019
Regeneron’s CD20xCD3 bispecific antibody has achieved an 80% complete response rate in a small trial of patients with relapsed or refractory follicular lymphoma....
Epizyme shuts down failing lymphoma trial as FDA imposes clinical hold pharmafile
August 06, 2018
Epizyme’s Q2 financial results have been derailed by the company’s decision to terminate further Phase 2 development of its lead drug tazemetostat in the treatment of relapsed and/or refractory diffuse large B-cell lymphoma (DLBCL), after an interim data
Kite Pharma climbs on strong data showing in lymphoma trial pharmafile
March 02, 2017
Kite Pharma released the news on Rare Diseases Day promising top-line data from a Phase 1/2 trial of its treatment for various types of non-Hodgkin lymphoma.